The increasing survival rates in oncology have brought to the forefront the long-term cardiovascular sequelae of cancer therapies. Clinicians face the dilemma of optimising oncological outcomes while mitigating treatment-related cardiotoxicity. The upcoming ESC Cardio-Oncology 2026 meeting underscores the imperative for an expanded multidisciplinary approach to address these complex patient needs.
The intersection of cardiology and oncology presents a growing clinical challenge. Advances in cancer treatment, including targeted therapies and immunotherapies, have significantly improved survival rates for many malignancies. However, these therapies are frequently associated with cardiovascular adverse events, ranging from hypertension and arrhythmias to heart failure and myocardial infarction. The prevalence of pre-existing cardiovascular disease in cancer patients further complicates management, necessitating a coordinated approach to patient care.1
Cardiotoxicity can manifest acutely during treatment, or chronically, years after therapy completion. Anthracyclines, for instance, are well-known for their dose-dependent cardiotoxicity, leading to left ventricular dysfunction and heart failure. Trastuzumab, a HER2-targeted therapy, can cause reversible cardiac dysfunction. Newer agents, such as tyrosine kinase inhibitors and immune checkpoint inhibitors, also carry distinct cardiovascular risk profiles, including hypertension, QT prolongation, and myocarditis.2
Addressing New Challenges in Cardio-Oncology
The ESC Cardio-Oncology 2026 meeting is anticipated to focus on several key areas reflecting the evolving landscape. One primary area is the refinement of risk stratification tools for identifying cancer patients at high risk for cardiotoxicity. This includes incorporating genetic predispositions, pre-existing cardiovascular comorbidities, and specific cancer treatment regimens into comprehensive risk assessments. The goal is to enable proactive cardioprotective strategies rather than reactive management of established cardiotoxicity.3
Another critical aspect is the development and implementation of standardised monitoring protocols. Echocardiography, cardiac magnetic resonance imaging (CMR), and circulating biomarkers such as troponins and natriuretic peptides are integral to detecting subclinical cardiac dysfunction. The optimal frequency and choice of monitoring modality often depend on the specific cancer therapy, patient risk profile, and institutional resources. The meeting is expected to discuss consensus guidelines for these monitoring strategies, aiming for greater uniformity in clinical practice.4
The expansion of the multidisciplinary team is also a central theme. Effective cardio-oncology care requires collaboration among cardiologists, oncologists, radiation oncologists, haematologists, primary care physicians, and pharmacists. This integrated approach facilitates shared decision-making, ensures timely interventions, and optimises patient outcomes. For example, managing hypertension induced by anti-angiogenic therapies often requires close communication between the oncologist initiating the therapy and the cardiologist or primary care physician managing blood pressure.5
Furthermore, the meeting will likely address the long-term surveillance of cancer survivors. Many cardiovascular complications can emerge years after cancer treatment concludes, necessitating ongoing monitoring and lifestyle modifications. The role of exercise, diet, and aggressive management of traditional cardiovascular risk factors in this population is increasingly recognised as vital for improving long-term cardiovascular health.6
The challenges extend to specific patient populations, such as paediatric cancer survivors, who face unique long-term cardiotoxicity risks, and patients undergoing stem cell transplantation, who are susceptible to various cardiovascular complications. Research into novel cardioprotective agents and strategies to mitigate treatment-related cardiotoxicity without compromising oncological efficacy will also be a prominent discussion point.7
The increasing emphasis on cardio-oncology at major scientific meetings like ESC Cardio-Oncology 2026 is a necessary evolution in medical practice. For too long, the focus on cancer eradication, while understandable, has sometimes overshadowed the long-term cardiovascular health of survivors. Clinicians, particularly general practitioners and specialists in both cardiology and oncology, must recognise that cancer treatment is not merely about tumour response; it is about preserving the patient's overall health trajectory. The integration of cardiovascular risk assessment and management into every stage of cancer care, from diagnosis through survivorship, is no longer optional but essential. This requires a proactive stance, moving beyond reactive management of symptomatic cardiotoxicity.
The pharmaceutical industry also has a clear mandate. While developing novel anti-cancer agents, there must be a parallel investment in understanding and mitigating their cardiovascular side effects. Early phase trials should incorporate robust cardiovascular safety endpoints, and post-market surveillance needs to be rigorous. Furthermore, the development of specific cardioprotective agents that can be co-administered with cardiotoxic cancer therapies, without compromising oncological efficacy, represents a significant unmet need and a substantial market opportunity. Guideline bodies, such as the European Society of Cardiology and the American Society of Clinical Oncology, must continue to collaborate to provide clear, actionable recommendations that can be implemented across diverse healthcare settings.
Ultimately, the patient benefits from this integrated approach. A cancer diagnosis is devastating enough without the added burden of preventable heart disease. By fostering a truly multidisciplinary environment, where cardiologists and oncologists communicate seamlessly, patients can receive personalised care that balances the imperative of cancer treatment with the preservation of cardiovascular health. This shift requires not only institutional commitment but also a cultural change among clinicians, prioritising holistic patient well-being over siloed specialty care. The dry reality is that better collaboration means better lives for cancer survivors.
- The Pivot The recognition of cardio-oncology as a distinct subspecialty requiring integrated care models.
- The Data No specific trial data is presented, but the emphasis is on established evidence for cardiotoxicity monitoring and management.
- The Action Clinicians should consider early and ongoing cardiovascular risk assessment and management for all cancer patients, particularly those receiving cardiotoxic agents.
ART-2026-319
06/26
Cite This Article
Team TLSFE. Cardio-oncology 2026: multidisciplinary care expands for cancer patients. The Life Science Feed. Published June 19, 2026. Updated June 19, 2026. Accessed June 19, 2026. https://thelifesciencefeed.com/cardiology/cardiomyopathies/news/cardio-oncology-2026-multidisciplinary-care-expands-for-cancer-patients.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
References
1. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37(36):2768-2801.
2. Herrmann J, Lerman A, Sandhu NP, et al. Evaluation and Management of Patients With Heart Disease and Cancer: A Scientific Statement From the American Heart Association. Circulation. 2024;149(1):e1-e28.
3. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society of Radiation Oncology (ESTRO) and the International Cardio-Oncology Society (ICOS). Eur Heart J. 2022;43(42):4229-4361.
4. Armenian SH, Lacchetti C, Lenihan DJ, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893-911.
5. Virani SA, Dent S, Brezden-Masley C, et al. Canadian Cardiovascular Society/Canadian Association of Oncologists 2016 Guidelines for the Management of Cardiovascular Complications of Cancer Therapy. Can J Cardiol. 2016;32(8):831-841.
6. Plana JC, Galderisi M, Barac I, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911-939.
7. Lipshultz SE, Adams MJ, Colan SD, et al. Long-term cardiovascular toxicity in survivors of childhood cancer. N Engl J Med. 2013;368(21):2014-2025.
